These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 21458261

  • 1. The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.
    Napier S, Wishart G, Arbuckle W, Baker J, Barn D, Bingham M, Brown A, Byford A, Claxton C, Craighead M, Buchanan K, Fielding L, Gibson L, Goodwin R, Goutcher S, Irving N, MacSweeney C, Milne R, Mort C, Presland J, Sloan H, Thomson F, Turnbull Z, Young T.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):3163-7. PubMed ID: 21458261
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
    Shimada Y, Taniguchi N, Matsuhisa A, Akane H, Kawano N, Suzuki T, Tobe T, Kakefuda A, Yatsu T, Tahara A, Tomura Y, Kusayama T, Wada K, Tsukada J, Orita M, Tsunoda T, Tanaka A.
    Bioorg Med Chem; 2006 Mar 15; 14(6):1827-37. PubMed ID: 16290163
    [Abstract] [Full Text] [Related]

  • 3. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
    Macion-Dazard R, Callahan N, Xu Z, Wu N, Thibonnier M, Shoham M.
    J Pharmacol Exp Ther; 2006 Feb 15; 316(2):564-71. PubMed ID: 16234409
    [Abstract] [Full Text] [Related]

  • 4. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands.
    Vangveravong S, Xu J, Zeng C, Mach RH.
    Bioorg Med Chem; 2006 Oct 15; 14(20):6988-97. PubMed ID: 16837201
    [Abstract] [Full Text] [Related]

  • 5. Identification of amide bioisosteres of triazole oxytocin antagonists.
    Brown A, Ellis D, Wallace O, Ralph M.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2224-8. PubMed ID: 20189387
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.
    Crombie AL, Antrilli TM, Campbell BA, Crandall DL, Failli AA, He Y, Kern JC, Moore WJ, Nogle LM, Trybulski EJ.
    Bioorg Med Chem Lett; 2010 Jun 15; 20(12):3742-5. PubMed ID: 20471258
    [Abstract] [Full Text] [Related]

  • 7. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S, Tanoue A, Koshimizu TA, Kitagawa Y, Tsujimoto G.
    Mol Pharmacol; 2004 Mar 15; 65(3):623-9. PubMed ID: 14978240
    [Abstract] [Full Text] [Related]

  • 8. Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.
    Wang L, Hubert JA, Lee SJ, Pan J, Qian S, Reitman ML, Strack AM, Weingarth DT, MacNeil DJ, Weber AE, Edmondson SD.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2911-5. PubMed ID: 21493064
    [Abstract] [Full Text] [Related]

  • 9. Electrophilic ipso-iodocyclization of N-(4-methylphenyl)propiolamides: selective synthesis of 8-methyleneazaspiro[4,5]trienes.
    Yu QF, Zhang YH, Yin Q, Tang BX, Tang RY, Zhong P, Li JH.
    J Org Chem; 2008 May 02; 73(9):3658-61. PubMed ID: 18376861
    [Abstract] [Full Text] [Related]

  • 10. Cyclic RGD-containing functionalized azabicycloalkane peptides as potent integrin antagonists for tumor targeting.
    Manzoni L, Belvisi L, Arosio D, Civera M, Pilkington-Miksa M, Potenza D, Caprini A, Araldi EM, Monferini E, Mancino M, Podestà F, Scolastico C.
    ChemMedChem; 2009 Apr 02; 4(4):615-32. PubMed ID: 19212960
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
    Xiang MA, Chen RH, Demarest KT, Gunnet J, Look R, Hageman W, Murray WV, Combs DW, Patel M.
    Bioorg Med Chem Lett; 2004 Jun 07; 14(11):2987-9. PubMed ID: 15125974
    [Abstract] [Full Text] [Related]

  • 12. Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.
    Johnson PS, Ryckmans T, Bryans J, Beal DM, Dack KN, Feeder N, Harrison A, Lewis M, Mason HJ, Mills J, Newman J, Pasquinet C, Rawson DJ, Roberts LR, Russell R, Spark D, Stobie A, Underwood TJ, Ward R, Wheeler S.
    Bioorg Med Chem Lett; 2011 Oct 01; 21(19):5684-7. PubMed ID: 21885275
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.
    Napier SE, Letourneau JJ, Ansari N, Auld DS, Baker J, Best S, Campbell-Wan L, Chan JH, Craighead M, Desai H, Goan KA, Ho KK, Hulskotte EG, MacSweeney CP, Milne R, Morphy JR, Neagu I, Ohlmeyer MH, Peeters AW, Presland J, Riviello C, Ruigt GS, Thomson FJ, Zanetakos HA, Zhao J, Webb ML.
    Bioorg Med Chem Lett; 2011 Mar 15; 21(6):1871-5. PubMed ID: 21353540
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.
    Napier SE, Letourneau JJ, Ansari N, Auld DS, Baker J, Best S, Campbell-Wan L, Chan R, Craighead M, Desai H, Ho KK, MacSweeney C, Milne R, Richard Morphy J, Neagu I, Ohlmeyer MH, Pick J, Presland J, Riviello C, Zanetakos HA, Zhao J, Webb ML.
    Bioorg Med Chem Lett; 2011 Jun 15; 21(12):3813-7. PubMed ID: 21596563
    [Abstract] [Full Text] [Related]

  • 15. Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.
    Baker J, Bingham M, Blackburn-Munro R, Cai J, Craighead M, Gilfillan R, Goan K, Jaap D, Milne R, Morphy JR, Napier S, Presland J, Spinks G, Thomson F.
    Bioorg Med Chem Lett; 2011 Jun 15; 21(12):3603-7. PubMed ID: 21601454
    [Abstract] [Full Text] [Related]

  • 16. Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2).
    Yang MG, Xiao Z, Shi Q, Cherney RJ, Tebben AJ, De Lucca GV, Santella JB, Mo R, Cvijic ME, Zhao Q, Barrish JC, Carter PH.
    Bioorg Med Chem Lett; 2012 Feb 01; 22(3):1384-7. PubMed ID: 22225639
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists.
    Eastwood P, Gonzalez J, Paredes S, Nueda A, Domenech T, Alberti J, Vidal B.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1697-700. PubMed ID: 20137946
    [Abstract] [Full Text] [Related]

  • 19. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms.
    Andrés M, Peña A, Derick S, Raufaste D, Trojnar J, Wisniewski K, Trueba M, Serradeil-Le Gal C, Guillon G.
    Eur J Pharmacol; 2004 Oct 06; 501(1-3):59-69. PubMed ID: 15464063
    [Abstract] [Full Text] [Related]

  • 20. Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior.
    Ferris CF, Lu SF, Messenger T, Guillon CD, Heindel N, Miller M, Koppel G, Robert Bruns F, Simon NG.
    Pharmacol Biochem Behav; 2006 Feb 06; 83(2):169-74. PubMed ID: 16504276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.